Monoamine neurotransmitter disorders—clinical advances and future perspectives
Authors:
Top Cited Papers
- 22 September 2015
- journal article
- review article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 11 (10) , 567-584
Abstract
The monoamine neurotransmitter disorders are important genetic syndromes that cause disturbances in catecholamine (dopamine, noradrenaline and adrenaline) and serotonin homeostasis. These disorders result in aberrant monoamine synthesis, metabolism and transport. The clinical phenotypes are predominantly neurological, and symptoms resemble other childhood neurological disorders, such as dystonic or dyskinetic cerebral palsy, hypoxic ischaemic encephalopathy and movement disorders. As a consequence, monoamine neurotransmitter disorders are under-recognized and often misdiagnosed. The diagnosis of monoamine neurotransmitter disorders requires detailed clinical assessment, cerebrospinal fluid neurotransmitter analysis and further supportive diagnostic investigations. Prompt and accurate diagnosis of neurotransmitter disorders is paramount, as many are responsive to treatment. The treatment is usually mechanism-based, with the aim to reverse disturbances of monoamine synthesis and/or metabolism. Therapeutic intervention can lead to complete resolution of motor symptoms in some conditions, and considerably improve quality of life in others. In this Review, we discuss the clinical features, diagnosis and management of monoamine neurotransmitter disorders, and consider novel concepts, the latest advances in research and future prospects for therapy.Keywords
This publication has 128 references indexed in Scilit:
- Dyskinesias as a Limiting Factor in the Treatment of Segawa DiseasePediatric Neurology, 2012
- De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: A genomics approach to personalized medicineEuropean Journal of Medical Genetics, 2012
- Cerebral vasculopathy is a common feature in Aicardi–Goutières syndrome associated with SAMHD1 mutationsProceedings of the National Academy of Sciences, 2011
- LRRK2 Mutant iPSC-Derived DA Neurons Demonstrate Increased Susceptibility to Oxidative StressCell Stem Cell, 2011
- Multiple coregulatory control of tyrosine hydroxylase gene transcriptionProceedings of the National Academy of Sciences, 2011
- Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental studyThe Lancet Neurology, 2011
- PhenylketonuriaThe Lancet, 2010
- Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency)Brain, 2010
- Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movementsEuropean Journal of Human Genetics, 2010
- Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystoniaJournal of Clinical Investigation, 2009